Industry highlights: switching from manual to automated hematopoietic stem cell (HSC) gene engineering

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

Genetic modification of CD34+ cells offers a promising approach for treating inherited disorders such as sickle cell disease, ß-thalassemia, and primary immunodeficiencies. Current manufacturing processes are often manual, involving significant handling and user interaction, which increases the risk of human error. Looking ahead to clinical trials and therapeutic applications, transitioning to an automated manufacturing process early can minimize user intervention and reduce clean room requirements. This shift leads to more reproducible and standardized manufacturing processes, ultimately resulting in safer cell products.

In this webinar, Ana Rubio from Orchard Therapeutics will provide valuable insights into transitioning from manual to automated hematopoietic stem cell gene engineering using the CliniMACS Prodigy® HSC Engineering process. She will also present data from a case study highlighting the benefits of this transition.

Attend this webinar to:

• Learn about the CliniMACS Prodigy® HSC Engineering process, which automates viral transduction of HSCs
• Discover how to transition from manual to automated HSC gene engineering
• Understand common challenges in automation and how to overcome them

Andreia Marques Gomes

Global Product Manager for Clinical Hematopoietic Stem Cell Portfolio at Miltenyi Biotec

Andreia conducted her PhD projects at the Icahn School of Medicine at Mount Sinai in New York where she has uncovered new mechanisms underlying hematopoietic reprogramming and definitive hematopoiesis specification. Andreia joined Miltenyi Biotec in 2023 and currently, as Global Product Manager for Hematopoietic Stem Cells Engineering, she works with her colleagues to develop automated, closed and scalable manufacturing solutions for hematopoietic stem cells in the CliniMACS Prodigy Platform.

Ana Rubio Gomes

Scientist II, Technical Development at Orchard Therapeutics

Ana is a passionate scientist with experience in gene and cell therapies, stem cell biology, immunology, and tissue regeneration. She has worked in various acclaimed academic institutions and biotechnology companies, including The Scripps Research Institute and Autolus Ltd.

She holds a BSc in Biotechnology from Universidad Europea de Madrid, an MSc in Genes, Drugs, and Stem Cells – Novel Therapies from Imperial College London, and a Postgraduate Diploma in Biotechnology Management from the University of California, Riverside.

Since 2021, Ana has worked at Orchard Therapeutics where she focuses on the design and implementation of HSC-based gene-modified cell manufacturing processes.

in 12

Days

Register

SPEAKERS

Andreia Marques Gomes

Global Product Manager for Clinical Hematopoietic Stem Cell Portfolio at Miltenyi Biotec

Ana Rubio Gomes

Scientist II, Technical Development at Orchard Therapeutics

You might also like

Ex vivo engineering of hematopoietic stem cells using RNA-LNPs for cell and gene therapies

Reka Geczy

2 July

Watch

Integrated plasmid engineering and manufacturing process: a unified approach from lab to clinic

Pauline Vieugué, PhD, Philippe Ledent, PhD

24 April

Watch

Mastering the journey from initial method transfer to successful lot release for cell & gene therapies

A Chang, H Malicki, J Cheung et al.

6 June

Watch

Accelerate the scale-up to clinical phase: optimizing stem cell culture performance and viral vector titers

Sara Bursomanno

24 April

Watch